Alcon's Q1 results strengthen case for higher Novartis bid
This article was originally published in Scrip
Executive Summary
Alcon bolstered its argument for securing a more beneficial takeover offer from Novartis with a 15% rise in its first-quarter sales to $1.7 billion and a 27% jump in net earnings to $573 million.